These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12027832)

  • 1. Olanzapine in Huntington's disease.
    Paleacu D; Anca M; Giladi N
    Acta Neurol Scand; 2002 Jun; 105(6):441-4. PubMed ID: 12027832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Tribl GG; Költringer P
    Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine for Huntington's disease: an open label study.
    Bonelli RM; Mahnert FA; Niederwieser G
    Clin Neuropharmacol; 2002; 25(5):263-5. PubMed ID: 12410058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and motor response to low dose olanzapine in Huntington's disease: case report.
    Laks J; Rocha M; Capitão C; Domingues RC; Ladeia G; Lima M; Engelhardt E
    Arq Neuropsiquiatr; 2004 Dec; 62(4):1092-4. PubMed ID: 15608976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole and olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Diez J; Költringer P
    Eur J Neurol; 2002 Mar; 9(2):183-4. PubMed ID: 11882065
    [No Abstract]   [Full Text] [Related]  

  • 6. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.
    Etchebehere EC; Lima MC; Passos W; Maciel Júnior JA; Santos AO; Ramos CD; Camargo EE
    Arq Neuropsiquiatr; 1999 Sep; 57(3B):863-6. PubMed ID: 10751925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term effects of olanzapine in Huntington disease.
    Squitieri F; Cannella M; Porcellini A; Brusa L; Simonelli M; Ruggieri S
    Neuropsychiatry Neuropsychol Behav Neurol; 2001 Jan; 14(1):69-72. PubMed ID: 11234911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of olanzapine for movement disorder in Huntington's disease: a first case report.
    Dipple HC
    J Neurol Neurosurg Psychiatry; 1999 Jul; 67(1):123-4. PubMed ID: 10454874
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.
    Benazzi F
    J Clin Psychopharmacol; 2002 Aug; 22(4):438-9. PubMed ID: 12172349
    [No Abstract]   [Full Text] [Related]  

  • 12. Olanzapine and Huntington's disease.
    Bogelman G; Hirschmann S; Modai I
    J Clin Psychopharmacol; 2001 Apr; 21(2):245-6. PubMed ID: 11270928
    [No Abstract]   [Full Text] [Related]  

  • 13. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.
    Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P
    J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apraxia of eyelid closure in Huntington's disease.
    Bonelli RM; Niederwieser G
    J Neural Transm (Vienna); 2002 Feb; 109(2):197-201. PubMed ID: 12075860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.
    Martin H; Slyk MP; Deymann S; Cornacchione MJ
    J Am Med Dir Assoc; 2003; 4(4):183-8. PubMed ID: 12837138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Olanzapine improves chorea in patients with Huntington's disease].
    Jiménez-Jiménez FJ; de Toledo M; Puertas I; Barón M; Zurdo M; Barcenilla B
    Rev Neurol; 2002 Sep 16-30; 35(6):524-5. PubMed ID: 12389168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of Huntington's disease with olanzapine and valproate.
    Grove VE; Quintanilla J; DeVaney GT
    N Engl J Med; 2000 Sep; 343(13):973-4. PubMed ID: 11012330
    [No Abstract]   [Full Text] [Related]  

  • 20. Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.
    Ishigooka J; Murasaki M; Miura S
    Psychiatry Clin Neurosci; 2000 Aug; 54(4):467-78. PubMed ID: 10997865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.